Recent developments include detailed Q1 2026 earnings disclosures and ongoing analyst coverage highlighting key financial metrics and operational updates.

• OrthoPediatrics reported a net loss of $10.687 million and EPS of -$0.45 for Q1 2026, with strong liquidity ratios including a current ratio of 5.21 and cash ratio of 1.03 as of March 31, 2026 [S2].
• The company’s Q1 2026 earnings transcript and report provide detailed insights into financial performance and business operations [N1][N2][N3].
• Q4 2025 earnings disclosures showed revenue exceeding estimates despite a net loss, with detailed earnings transcripts available [N6][N7][N8].
• Multiple analyst reports and news articles have covered OrthoPediatrics’ recent earnings and key metrics, reflecting active market interest [N4][N5].

The company demonstrates strong liquidity and ongoing operational transparency through regular earnings disclosures. Continued focus on pediatric orthopedic solutions may support steady business activity and market interest, as reflected in analyst coverage and news reports.

The company reported a net loss in the most recent quarter, indicating ongoing profitability challenges. The specialized market focus may limit scale, and the absence of detailed sector or industry data constrains visibility into competitive positioning and growth dynamics.

OrthoPediatrics operates in a specialized niche within the medical device industry focused on pediatric orthopedics, which may provide some differentiation. However, specific competitive advantages or barriers to entry are not detailed in the available disclosures.

• Profitability Risk: The company reported a net loss of $10.687 million in Q1 2026, indicating challenges in achieving profitability.
• Market and Competitive Risk: Limited public information on sector and industry specifics restricts clarity on competitive pressures and market dynamics.
• Liquidity Risk: Although liquidity ratios are strong as of Q1 2026, ongoing operational losses could impact future financial stability if not addressed.

• OrthoPediatrics Corp operates in the medical device sector focused on pediatric orthopedics.
• The company reported revenue of $98.05 million for the fiscal year ended December 31, 2021, as per its 10-K filing [S1].
• For the quarter ended March 31, 2026, OrthoPediatrics reported a net loss of $10.687 million and basic and diluted EPS of -$0.45 per share [S2].
• As of March 31, 2026, the company held $12.193 million in cash and cash equivalents and $36.616 million in short-term investments, totaling $48.809 million in liquid assets [S2].
• Current assets as of March 31, 2026, were $245.866 million, with current liabilities of $47.183 million, resulting in a current ratio of 5.21 and a cash ratio of 1.03, indicating strong liquidity [S2].
• Recent quarterly earnings reports and transcripts from Q4 2025 and Q1 2026 provide detailed insights into financial performance and operational updates [N1][N6].
• The company has been covered by multiple analyst reports and news articles discussing earnings results and key metrics, reflecting active market interest and transparency [N2][N3][N7][N8].